Abstract

This proposal investigates the relationship between markers of angiogenesis in colorectal tumors and treatment outcome with a regimen containing bevacizumab, an anti-VEGF antibody. The proposal also explores the determinants of the biology of angiogenesis, the effects of its inhibition on tumor cell survival, and the sources of interpatient pharmacogenetic variability that may underlie treatment effects with 5-fluorouracil, oxaliplatin and bevacizumab. To accomplish these objectives, the proposal utilizes tumor blocks collected through the Eastern Cooperative Oncology Group (ECOG) Trial E3200, a randomized study of 5-fluorouracil, Oxaliplatin With or Without Bevacizumab. ? ?

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA111874-01
Application #
6858004
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Xie, Heng
Project Start
2005-07-06
Project End
2007-06-30
Budget Start
2005-07-06
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$136,310
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Chen, Shao-Hua; Murphy, Danielle A; Lassoued, Wiem et al. (2008) Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7:1994-2003
Selvakumaran, Muthu; Yao, Kang Shen; Feldman, Michael D et al. (2008) Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 75:627-38